Annals of the New York Academy of Sciences 1995: Vol 748 Index

17 Pages·1995·3.4 MB·English

Index of Contributors
(Italicized numbers refer to comments made in discussion)
Aixawa, M. 578-585 Fujita, H. 133-147
Akakura, H. 394-398 Fujitani, N. 534-537
Akita, H. 626-629 Furuya, M. 517-523
Albers, J. J. 407-417
Ali Elsayed, Y. 185-192 Gaiis. Z. S. 158-168, 501-507
Ando, J. 148-156, 156 Gimbrone, M. A. 39, 12], 122-131, 131-132,
Arai, H. 294-300 156-157, 282, 312, 381-382, 471,
Arai, T. 599-602, 606-608
480-481, 541-542
Arisaka, T. 543-554 Gotoda, T. 357-364
Asada, Y. 74-85 Griem, M. L. 86-102
Asaoka, H. 226-238 Gryglewski, R. J. 194-206, 207, 392-393
Ashikaga, T. 383-392
Eke. H. 626-629
Baker. J. E. 474-480, 559-561 Hagiwara, H. 104-120
Balyasnikova, I. V. 12-37 Haibach, C. 301-311
Barbee, K. A. 86-102 Hakoi, K. 640-644
Bini, A. 293, 461-471, 471-473 Hamazaki, Y. 630-633
Bouché, A. 367-381 Han, S.-Z. 447-460
Brown, B. G. 3/2, 332, 355, 407-417, Harada, K. 357-364
417-418, 428 Harada-Shiba, M. 429-439
Buchwald, H. 4-5, 33/7, 342-355, 355-356, Haraki, T. 333-341
418 Haraoka, S. 40-55
Bystrevskaya, V. B. 12-37 Hashimoto, H. 626-629
Byzova, T. V. 12-37 Hasler-Rapacz, J. 283-292
Hata, A. 383-392
ae C. T. for the POSCH Group Hata, Y. 183-184
342-355 Hatano, H. 226-238
Carmeliet, P. 367-381 Haust, D. 168, 300, 331, 471
Chlopicki, S. 194-206 Hayashi, T. 74-85
Collen, D. 367-381, 38]-382 Higashino, H. 534-537
Collins, T. 122-131 Hillger, L. 407-417
Currier, J. W. 419-427 Hirai, A. 571-574
Cybulsky, M. I. 122-131 Hirano, K. 599-602, 606-608
Hirata, K. 555-558
Hirose, S. 543-554
Davies, P. F. 55-56, 86-102, 102-103,
Honbou, N. 517-523
156-157, 183, 382
Honda, M. 226-238
De Clercq, C. 367-381
Honye, J. 494-497
Doi, T. 226-238
Hoshino, A. 217-224
Doi, Y. 634-636
Hosoda, S. 208-216
Hosoi, T. 530-533
an A. 474-480, 559-561
Egashira, K. 622-625
Lenikawa, K. 185-192
Ejiri, N. 595-598
lijima, H. 217-224
Emi, M. 226-238
lino, K. 634-636
Endo, Y. 630-633
Ikeda, M. 637-639
Epstein, F. H. 482-490 Ikewaki, K. 441-446, 626-629
Ilyinskaya, O. P. 12-37
a D. P. 216, 419-427, 427-428 Imanaka, T. 277-281, 524-525
Fujinuma, Y. 595-598 Inaba, T. 357-364
Fujisawa, K. 562-570, 595-598 Inazu, A. 333-341
Fujishima, M. 634-636 Inoue, S. 530-533, 592-594
652 ANNALS NEW YORK ACADEMY OF SCIENCES
Ishibashi, T. 630-633 Kumabashiri, I. 394-398
Ishigami, M. 606-608 Kume, N. 122-131, 541-542
Ishikawa, T. 626-629 Kuro-o, M. 578-585
Itakura, H. 226-238 Kuroda, R. 555-558
Ito, T. 626-629 Kuzuya, F. 510-513
Iwasaki, K. 524-525 Kwiterovich, P. O. 2/6, 224, 238, 292, 300,
Iwase, M. 634-636 311, 313-330, 331-332, 417, 440, 446
, re S. 367-381 Lai R. 86-102
Jimi, S$. 609-612 Latsis, R. V. 12-37
Jokaji, H. 394-398 Leight, M. A. 264-275
Libby, P. 37-38, 121, 158-168, 168-170, 207,
Died. K. 333-341 365, 472, 480, 501-507, 526-529
Kameda-Takemura, K. 599-602, 606-608 Lingenhel, A. 301-311
Kamiya, A. 148-156 Liu, P.-M. 494-497
Kangawa, K. 517-523 Loskutoff, D. J. 137, 177-183, 183-184, 192,
Kanmatsuse, K. 494-497 473
Karaki, H. 447-460
Kario, K. 398
Mhabuchi, H. 333-341, 34]
Katayama, M. 555-558
Makino, K. 603-605
Kato, K. 185-192
Makita, T. 383-392, 640-644
Katsura, Y. 57-72
Manabe, I. 578-585
Katsurada, M. 626-629
Marutsuka, K. 74-85
Kawahara, Y. 586-589
Maruyama, Y. 630-633
Kawai, C. 208-216
Mastrangelo, A. 474-480, 559-561
Kawamura, M. 357-364
Masuda, J. 171-175, 491-493, 508-509,
Kawarabayasi, Y. 217-224, 630-633
538-540, 590-591
Kawashima, K. 517-523
Matsuda, T. /83, 394-398, 398
Kawashima, S. 555-558
Matsumoto, A. 226-238
Kawasumi, M. 104-120, 543-554
Matsumura, S. 534-537
Kawazoye, S. 534-537
Matsuo, H. 517-523
Keno, Y. 399-406
Matsuse, T. 530-533
Kim, D. N. 474-480, 480-481, 559-561
Matsushita, H. 333-341
Kim, H.-S. 578-585
Matsuzawa, Y. 399-406, 406, 599-602,
Kino, T. 571-574
606-608
Kinukawa, N. 494-497
Mayes, P. A. 240-262, 263
Kishi, Y. 383-392
Mindham, M. A. 240-262
Kishikawa, H. 40-55
Mitsumata, M. 104-120, 543-554
Kishino, B. 429-439
Miyasaka, M. 148-156
Kita, T. 294-300, 541-542
Miyazaki, T. 517-523
Kobayashi, M. 104-120
Mori, M. 277-281, 524-525
Kochl, S. 301-311
Mort, T. 226—238
Kodama, T. 226-238, 238-239
Morisaka, N. 575-577
Koga, N. 429-439
Morishita, E. 394-398
Koide, M. 586-589
Morita, I. 133-147
Koizumi, J. 333-341
Moriuchi, M. 494-497
Kojima, S. 429-439
Morohoshi, M. 562-570, 595-598
Komine, Y. 524-525
Mulligan, R. C. 367-381
Korenaga, R. 148-156
Murakoshi, S. 626-629
Kosaka, C. 171-175, 491-493, 508-509,
Muramatsu, M. 530-533
538-540, 590-591
Murota, S. 133-147, 147
Kosanuki, A. 74-85
Muszynski, M. 501-507
Koyama, N. 575-577
Kozaki, K. 530-533
Kraft, H. G. 301-311 Nazai, R. 578-585
Krushinsky, A. V. 12-37 Nagano, Y. 294-300
Kudryk, B. J. 461-471 Naito, M. 226-238
INDEX OF CONTRIBUTORS
Nakagawa, K. 185-192 Sato, Y. 74-85
Nakajima, K. 595-598 Sawamura, F. 637-639
Nakamura, H. 226-238, 441-446, Scanu, A. M. 603-605
626-629 Schmee, J. 474-480
Nakamura, T. 399-406 Schwartz, D. 526-529
Nakashima, Y. 514-516 Seiffert, D. 177-183
Nakayama, I. 586-589 Sethi, S. 474-480
Namoto, M. 185-192 Sheikh, A. 494-497
Niezabitowski, P. 194-206 Shige, H. 441-446
Nishi, E. 541-542 Shima, K. 277-281
Nishiwaki, M. 441-446, 626-629 Shimada, M. 357-364
Noma, A. 603-605 Shimajiri, S. 514-516
Nozaki, S. 599-602 Shimokado, K. /02, 171-175, 175-176,
Numano, F. xiii, 6, 770, 383-392, - 491-493, 508-509, 538-540, 590-591
562-570, 595-598 Shimokama, T. 40-55
Shimokata, H. 510-513
Shimomura, I. 399-406
Oxi. H. 541-542
Shindo, J. 630-633
Ogata, J. 171-175, 491-493, 508-509,
Shiomi, M. 630-633
538-540, 590-591
Simon-Morrissey, E. 501-507
Ohashi, Y. 555-558
Ohno, T. 517-523 Sinzinger, H. 613-621
Onsuga, J. 357-364 Smirnov, V. N. 12-37, 37-39, 102, 224, 366,
Okano, M. 104-120 418, 440
Orimo, A. 530-533, 592-594 Soboleva, E. L. 12-37
Orimo, H. 447-460, 530-533, 592-594 St. Clair, R. W. 5-6, 224, 264-275, 276, 355
Ouchi, Y. 447-460, 530-533, 592-594 365, 428
Stein, R. J. 57-72
Stergiopoulos, K. 447-460
Pisich, C. 613-621 Sueishi, K. 185-192, /92-]93
Pollefeyt, S. 367-381
Poulin, D. 407-417 Sukhova, G. K. 501-507, 526-529
Pravastatin Restenosis Trial Study Group Sumiyoshi, A. 74-85, 85
208-216 Sunaga, T. 534-537
Prescott, M. F. 38, 169, 238, 283-292, Suzuki, A. 526-529, 534-537
292-32319, 3341,, 3 93 Suzuki, T. 534-537
Swies,J . 194-206
_ J. 283-292
Resnick, N. 122-131
"Bes, R. E. 447-460
Robertson, A. L. 55, 57-72, 72-73, 120
Takada, Y. 148-156
Robotewskyj, A. 86-102
Takahashi, K. 226-238
Romanov, Y. A. 12-37
Takahashi, S. 217-224, 630-633
Ross, J. S. 474-480, 559-561
Takamiya, M. 429-439
Ross, R. 1-4, 5-6, 10, 38, 132, 147, 192,
Takano, T. 277-281, 28]-282, 524-525
238-239, 276, 281, 418, 427-428
Takashima, T. 534-537
Takebayashi, S. 609-612
Sagi A. M. 514-516 Takei, H. 514-516
Saito, M. 394-398 Takeshita, A. 622-625
Saito, S. 494-497 Tamamoto, T. 514-516
Saito, Y. 7-10, /0-11, 575-577 Tamura, M. 595-598
Sakai, J. 217-224 Tamura, Y. 571-574
Sakai, N. 599-602, 606-608 Tanaka, A. 595-598
Sakata, N. 609-612 Tanaka, H. 47/-473, 526-529
Sakurai, I. 494-497 Tanaka, K. /2/
Sasaguri, T. 171-175, 491-493, 508-509, Tanaka, S. 517-523
538-540, 590-591 Tararak, E. M. 12-37
Sato, R. 524-525 Tatami, R. 429-439
Sato, T. 630-633 Thomas, W. A. 474-480
654 ANNALS NEW YORK ACADEMY OF SCIENCES
Tian, S.-F. 534-537 Watanabe, M. 578-585
Toda, S. 534-537 Watanabe, R. 383-392
Toda, T. 514-516 Watanabe, T. 40—55, 55-56
Tohjima, T. 543-554 Watanabe, Y. 357-364
Tokinaga, K. 571-574 Wissler, R. W. 37, 56, 73, 85, 169, 183, 275,
Tokunaga, K. 399-406, 606-608 293, 300, 311-312, 365, 471, 645-650
Tokunaga, O. 498-500 Wyns, S. 367-381
Tomita, I. 637-639
Tomita, T. 637-639 YVasi, K. 333-341
Tomiyasu, K. 626-629 Yamada, N. 357-364, 364-366
Toyama-Sorimachi, N. 148-156 Yamaguchi, H. 578-585
Toyota, Y. 429-439 Yamamoto, A. 429-439, 439-440
Trommsdorff, M. 301-311 Yamamoto, M. 634-636
Tsuboi, H. 148-156 Yamamoto, T. 217-224, 224-225, 630-633
Tsuda, T. 586-589 Yamashita, S. 599-602, 606-608
Tsuneyoshi, A. 74-85 Yamazaki, M. 394-398
Tsushima, M. 429-439 Yancey, P. G. 264-275
Yazaki, Y. 226-238, 357-364, 578-585
ee 1. 562-570, 595-598 Yokode, M. 225, 294-300, 300
Uetsuka, R. 637-639 Yokota, T. 171-175
Ueyama, K. 294-300 Yokoyama, K. 630-633
Uotani, C. 394-398
Utermann, G. 293, 301-311, 311-312, Yoshida, S. 571-574, 575-577
331-332, 341 Yoshida, Y. 104-120, 120-121, 543-554,
599-602
Yoshinari, M. 634-636
Van Aken, B. E. 177-183 Yui, K. 595-598
Von Linden-Reed, J. 283-292 Yui, Y. 208-216, 216
Yutani, C. 491-493
Wasa. Y. 226-238
Wakabayashi, Y. 133-147 im: K. 171-175, 491-493, 508-509,
Wakimoto, N. 626-629 538-540, 590-591
Wang, S. 104-120 Zhao, X.-Q. 407-417
Subject Index
A A. See Arachidonic acid Antiproliferative agents, 421-423
ACAT. See Acyl-CoA:cholesterol Apolipoprotein A (ApoA), 313
acyltransferase in CAD family children, 315
ACE inhibitors. See Angiotensin-converting- in HDL, 240-241, 247-248, 251-252
enzyme inhibitors obesity in youth and, 316
Activated platelets and RCT, 251-253
cytotoxicity of, 383-385 Apolipoprotein(a) [Apo(a)]
and EC dysfunction, 385-387 as atherosclerosis risk factor, 190
and PDGF release, 78 in atherosclerotic intima, 185
and thrombus formation, 383 and CHD, 308-309
Activin, 530-531 immunohistological distribution of, 189
Acute phase proteins, 466, 562 in premature CAD, 313
Acyl-CoA:cholesterol acyltransferase Apolipoprotein B (Apo B)
(ACAT), 195. See also Cholestery] and atherosclerosis, 313
ester hydrolase and CAD, 283-291, 315
in cholesterol metabolism, 264, 270-271, Apolipoprotein B (Apo B) genotype
357, 359-363
cholesterol levels in, 284-288, 290-291
heparin inhibition of, 636
coronary artery stenosis in, 285-291
M-CSF and, 360
Apolipoprotein B-100 (Apo B-100), 595
Adhesion molecules, 148, 150-153, 155. See
Apolipoprotein C (apo C), 247-248, 251-252
also ELAMs; ICAM-1; VCAM-1
Apolipoprotein E (Apo EB), 240-241, 248,
and EC injury, 136-138, 144 250-252, 441, 444-445
in leukocyte-endothelial adhesion,
123-126, 133-134 Apolipoprotein E-containing lipoproteins,
219; 222
in peroxide production, 133-139
Apolipoproteins
signal transduction via, 144-145
CS alteration of, 299
and xanthine oxidase activation, 134,
in HDL, 246-248
141-146
Advanced glycosylation end products liver uptake of, 259
(AGEs), 562, 564, 566-569 Arachidonic acid (AA), 194, 476. See also
AGEs. See Advanced glycosylation end Eicosapentaenoic acid
NOS inhibition by, 556-558
products
Alcohol consumption, and lipoprotein levels, and platelet aggregation, 78
626-629 Arteriosclerosis Specialized Center of
Amaurosis fugax, 491 Research Study, 351
American Heart Association (AHA) Phase Arteriosclerotic lesions, follistatin expression
II diet, 343 in, 530-532
and atherosclerosis, 313 Artery-to-artery thromboembolism, 491-493
and CHD, 295 as negative atherosclerosis risk factor,
and cholesterol efflux, 295 336-337
and PGI, synthesis, 194 Aspirin (ASA)
Aneurysm, in atherosclerosis, 163 antiplatelet effects of, 420-421
Angina pectoris, TXAg in, 195 antithrombolytic effects of, 200-201
Angioplasty. See Percutaneous transluminal and hepatomegaly, 640, 642
coronary angioplasty and monocyte-EC interaction, 560
Angiotensin-converting-enzyme (ACE) and peroxisome proliferation, 640-643
inhibitors, 421-423 and PGI,/NO release, 199-201
and restenosis, 420-421 and platelet adhesion, 78
Angiotensin II, 187 and TXA; formation, 195
ANP. See Natriuretic peptides ATHERO-ELAM
Anticoagulants, for restenosis, 421-422 and atherogenesis, 125
Antiplatelet therapy characterization of, 124
for ischemic heart disease, 387-391 expression of, 125-126
for restenosis, 420-422 pathophysiologic implications of, 126
for thrombosis, 78 ATHERO-ELAM hypothesis, 123-126
656 ANNALS NEW YORK ACADEMY OF SCIENCES
Atherogenesis Atherosclerotic aorta
arterial cell proliferation in, 58 procoagulant properties of, 185
ATHERO-ELAM hypothesis of, 123-126 TF localization in, 186-187
cytokine influences on, 160-161 Atherosclerotic lesions, 1
EC inflammatory-proliferative responses apo(a) in, 185
and, 68-69 c-myc expression in, 514-515
hemodynamics and, 86-88 comparative evaluation of, 494-497
HSV and, 57-60, 66-69 EC polymorphism and, 12
immunologic implications in, 49-53 fatty streaks and, 41, 313
leukocyte clusters and, 25 follistatin in, 530-532
macrophages in, 40-41, 47-
macrophage-SM fibroproliferative
response and, 2 multinucleated EC increase and, 14
prelesional change and, 44 T lymphocytes in, 40-53
vitronectins in, 524-525
SMC proliferation in, 313
in youth, 313-314
T lymphocyte—macrophage interaction in,
42, 44-53 lipid risk factors for, 313-315
nonlipid risk factors for, 315-318
transformed cell clones and, 58-59, 66-69
Atherosclerotic plaque
Atheroma
hypercoagulability of, 186-187
coagulation/fibrinolysis components in,
M-CSF roles in, 160
465-466
molecular characterization of, 463-464
cytokines in, 158 Atomic force microscopy (AFM), 90-95
inflammatory-proliferative responses and, Atrial natriuretic peptide (ANP), 384,
57-58 517-519, 521
TF in, 186-187
Atheromatous embolism, 491-493
B altimore Longitudinal Study of Aging
Atheromatous plaques, 185
(BLSA), 511
T lymphocytes in, 47-49
Brain infarcts, 491-493
Atherosclerosis
apo B genotype and, 285-291
apolipoproteins and, 190, 313, 445 C a** antagonists, and restenosis, 421-422
ATHERO-ELAM hypothesis, 123-126 Ca?* channel blockers
decreased HDL levels and, 283 antiatherogenic effect of, 195, 447
in diabetes mellitus, 562 estrogen as, 449-458
MG?" as, 448-449
ECM dysregulation in, 501-506
‘a** levels
EC proliferative activity and, 12
elevated LDL levels and, 283, 290 activated platelets and, 384
Ca?* mobilization and, 385
endothelial heterogeneity and, 14-17, 32
CAD. See Coronary artery disease
leukocyte adhesion in, 123-126
M-CSF in, 357-363 cAMP-dependent kinase (A-kinase),
638-639
multifactorial events in, 57-58
PDAY study, 314 cAMP-elevating cytokines, 586-589
cAMP levels, vascular injury and, 384
PDGF in, 8-10
CD. See Adhesion molecules
PGI) suppression in, 194-195
CD4+/CD8+ cells. See T lymphocytes
PKC activation and, 539-540 CE. See Cholesteryl ester
prevention of, 447-458 Cell migration/proliferation, 2-3
regression of, 429-437 CFUs. See Colony-forming units
response-to-injury hypothesis of, 3, 383, Cholesterol. See also Lipoproteins
538 liver uptake of, 254-255
risk factors for, 177, 313-318 macrophage uptake of, 264-274
PIB control of, 342, 344-345, 348 metabolism of
POSCH and, 342-352 ACAT in, 357, 359-360, 362-363
SMC migration and, 2, 34 heparin and, 634-646
syndrome X and, 400 in macrophages, 357-363
thrombosis and, 462-463, 467-468 Cholesterol levels
TXA; in, 195 after LDL-apheresis, 436
in youth, 313-318, 328 apo B genotype and, 284-291
SUBJECT INDEX 657
and cancer, 483-485, 488 and hypo-LDL-cholesterolemia, 340
and cardiovascular disease, 483-488 lipoprotein abnormalities in, 599, 606
dietary approach to, 319-328 and longevity syndrome, 336-337
diets for. See also American Heart LPL activities in, 600-602
Association diet and RCT impairment, 601-602
and disease Chylomicron remnants, 334, 441-445
in low- vs. high-cholesterol countries, Cigarette-smoke-modified HDL (CS-HDL),
482-488 298-299
preventive strategies, 485-488 Cigarette-smoke-modified LDL (CS-LDL)
U-shaped relationship of, 487 characteristics of, 295-296
and fibrinogen levels, 467 and macrophage foam cell transformation,
fish oils and, 474-475 296-299
GM-CSF and, 630-632 Cigarette smoking
and hemorrhagic stroke, 486-488 as atherosclerosis risk factor, 343
longitudinal changes in, 510-513 and CAD, 28, 313, 318
and mortality and fibrinogen level, 467
from cancer, 483-485, 488 and IHD risk, 467
from cardiovascular disease, 484-485 CMV. See Cytomegalovirus
J-shaped relationship for, 483-485, 487 C-myc expression, in atherosclerotic lesions,
noncardiovascular-noncancer, 482-488 514-515
non-illness-related, 484-485 CNP. See Natriuretic peptides
PIB and, 342, 344-345 Collagens
in Sumo wrestlers, 402 in atheroma, 163
Cholesterol Lowering Atherosclerosis Study oxLDL binding with, 609-611
(CLAS), 344, 351, 415 in vascular ECM, 163
Cholesterol-lowering therapy, 622-625 Colony-forming units (CFUs), 33, 35
Cholesterol reverse transport. See Reverse in early atherogenesis stages, 25-30
cholesterol transport hypercholesterolemia and, 32
Cholesterol transport Colony-stimulating factor (CSF), 33
from spleen to blood, 245-246 Coronary artery bypass graft (CABG), 333
from spleen to HDL, 246-249 in POSCH, 344, 346-348, 352
Cholesterol transport disorders, 333-340 Coronary artery disease (CAD). See also
Cholesteryl ester (CE) Premature coronary artery disease
estrogen-enhanced hydrolysis of, 638-639 apo B levels and, 283-291, 315
in RCT, 601-602, 606 in children of CAD parent, 315
VHDL and, 607-608 cholesterol blood levels and, 314-318
Cholesteryl ester (CE) hydrolase. See also dyslipidemias associated with, 283-284
Acyl-CoA:cholesterol transferase dyslipoproteinemias in, 320-323
in cholesterol metabolism, 357, 359-360, fat distribution in, 400
362-363 FCHL gene and, 315
Cholesteryl ester (CE) metabolism, 637-639 HDL levels in, 315
Cholesteryl ester transfer protein (CETP) inherited dyslipidemia gene in, 315
function of, 333-334, 599, 602, 606 LDL levels and, 283, 290
in HDL-to-VHDL transformation, 608 NCEP dietary recommendations, 319
mutant genes of, 339 postprandial hyperlipemia and, 441-445
in RCT, 606-608 risk factors for, 328
Cholesteryl ester transfer protein (CETP) Coronary heart disease (CHD)
deficiency apo(a) polymorphism and, 308-309
alcohol intake and, 626-629 FH-CETP deficiency combination and,
and atherosclerosis incidence, 336 339-340
and CHD, 339-340 HDL and, 295, 599
in familial hyper-HDL-cholesterolemia, Lp(a) concentrations and, 301
336-340 mortality in POSCH, 344-346, 350
gene mutations in, 599 PIB and, 342
and HALP, 599 RLP levels in, 595-598
HDL levels in, 601-602, 606 Coronary stenosis changes. See Familial
HTGL activities in, 599-602 Atherosclerosis Treatment Study
658 ANNALS NEW YORK ACADEMY OF SCIENCES
CRT. See Reverse cholestero! transport GAG synthesis in, 543-552
CS-LDL. See Cigarette-smoke -modified LDL in high shear-stress regions, 106
C-type natriuretic peptide (CNP), 517-523 injury to
Cyclins, 538-540 adhesion molecules role in, 133-134,
Cyotkines 136-138, 144
in atherogenesis, 158-165 oxidative stress and, 133-146
immunologic implications of, 50-53, 69 in low shear-stress regions, 105-106, 114,
and atheroma progression, 57-58, 160-161 116
in collagen synthesis regulation, 163 lumenal surface features, 90-95
and cytokine/growth factor genes, 159-160 mechanotransduction at, 88-89
foam cell formation and, 2 morphological heterogeneity of, 12, 14-17
intimal expression of, 44, 46 proliferation
and leukocyte adhesion molecules, and atherosclerosis, 12, 14, 32-33
123-125, 158-159 in HP and LP zones, 15-16, 32-33
in NOS induction, 586-589 PKC pathway inhibition of, 538-540
and prelesional changes, 44 and SMC phenotype change, 7, 9
and pro- and antiatherogenic actions, tension and, 89-90
160-161, 164-165 Endothelial dysfunction
and vascular cell-blood compatibility, and atherosclerosis, 122
161-162 hemodynamic induction of, 126-128
and vascular ECM homeostasis, 162-164 oxidative stress and, 133-146
and vasomotor arterial tone, 161 SSRE in, 123, 128, 155
Cytomegalovirus (CMV), 58, 67 Endothelial-leukocyte adhesion molecules
(ELAMs), 123-124
D AG. See 1,2-Diacylglycerol and early atherosclerotic lesions, 124-125
in ECs, 498-500
Deadly quartet, 400
Diabetes mellitus. See also EPA effects on, 478-479
Insulin-dependent diabetes mellitus IL-1 induction of, 475
as atherosclerosis risk factor, 343 Endothelial permeability
and atherosclerosis, 114, 116, 118-119
atherosclerotic pathogenesis in, 562
and CAD, 313, 318, 328 for macromolecules, 106
hyperfibrinogenemia in, 568-569 Endothelium
1,2-Diacylglycerol (DAG), 2, 538-540 as complex organ, 122
Diarrhea, as PIB side effect, 345, 348 and leukocyte-selective adhesion, 19,
Diet and Reinfarction Trial (DART), 467 22-25, 123-126. See also ELAMs
Dyslipidemia. See also Hypercholesterolemia as pathophysiologic milieu integrator, 129
and CAd, 283-284 Endothelium-dependent vasodilation,
622-625
in CAD family children, 315, 318
genetic determinants of, 283, 315 EPA. See Eicosapentaenoic acid
Dyslipoproteinemia, 314 E-selectin (ELAM-1), 124-125, 154, 541-542
Estrogen
antiatherogenic effects of, 449--458, 637
E CM. See Extracellular matrix in CE metabolism, 637-639
Ectasia, 163 Estrogen receptor (ER), in VSMC, 592-594
Eicosapentaenoic acid (EPA), 467, 474-479 Extracellular matrix (ECM)
ELAM. See Endothelial-leukocyte adhesion dysregulation, 501-506
molecules; E-selectin organization, 534-537
Endothelial cells (ECs). See also Human
aortic endothelial cells; Human
umbilical vein endothelial cells F actor VII, 394-396, 398
ablumenal surface features, 95-100 Familial Atherosclerosis Treatment Study
activated platelet effects on, 383-387 (FATS), 351
adhesion properties of coronary lesion change, 410-411
GMP-140 and, 18-19 lesion progression/regression, 413-414
and leukocyte binding, 22-24 lipid-altering strategies in, 407-408
balloon injury activation of, 526-528 results, 415-417
cAMP changes in, 383-384 Familial combined hyperlipidemia (FCHL),
dysfunction of, 385-388 315, 324
SUBJECT INDEX 659
Familial hyperalphaproteinemia, 336-337, hypothrombotic/hypospasmodic effects of,
339. See also Familial hyper-HDL- 474
cholesterolemia and IHD mortality, 479
and monocyte-EC interactions, 475-479
apheresis therapy for, 430-435 in restenosis prevention, 421-422
and atherosclerosis, 283-291 Foam cells
and CAD risk, 314-315 in atheromatous plaques, 47-48
genetic basis of, 324 and fatty streak formation, 41, 44-47, 123
in LARS, 435-436 formation of
LDL-receptor abnormalities in, 333-336 apo E in, 445
CS-LDL and, 295-298
and premature CAD, 324
Familial hyper-HDL-cholesterolemia, SCP, and, 571-574
336, 339. See also Familial macrophage transformation and, 41, 44,
123
hyperalphaproteinemia
TF expression in, 186-187
Familial hypertriglyceridemia (FHT), 325
Follistatin expression, 530-532
Fatty acids
in fish oils, 474-476
and monocyte adhesion, 476-479 G AG. See Glycosaminoglycan
n-3 fatty acids. See Eicosapentaenoic acid Gangliosides. See Asialo GM2 in fatty
n-6 fatty acids. See Arachidonic acid streaks, 277-281
Fatty streaks, 44-47 GC. See Guanyl cyclases
and atherosclerotic lesions, 41 Glucose, and cytokine production, 562-564,
568-569
cholesterol levels and, 314
as earliest atherosclerotic lesion, 313 Glycosaminoglycan (GAG) synthesis,
543-552
foam cells and, 123
GM2. See Gangliosides
ganglioside deposition in, 277-281
GM-CSF. See Granulocyte-macrophage
TF expression in, 187-188, 190
FCHL. See Familial combined colony-stimulating factor
GMP-140, 154
hyperlipidemia
in EC-leukocyte interactions, 24
FHT. See Familial hypertriglyceridemia
expression
Fibrin
under hemodynamic flow, 19-21
in atherosclerotic plaques, 463-465
in human aortic endothelium, 18-19
immunohistological distribution of, Granulocyte-macrophage colony-stimulating
189-190 factor (GM-CSF), 630-632
Fibrinogen Guanyl cyclases (GC)
as acute phase protein, 562 as CNP receptor, 517
in atherosclerosis, 461-468 in injured arteries, 519, 522-523
Fibrinogen levels. See also as NP receptors, 517, 519
Hyperfibrinogenemia SMC expression of, 518
as cardiovascular disease risk factor, 562,
567
H AEC. See Human aortic endothelial
in diabetes, 568-569
cells
fish oils and, 467
HALP. See Hyperalphalipoproteinemia
IL-6 levels and, 562, 568-569 HB-EGF. See Herparin-binding EGF-like
smoking and, 467 growth factor
Fibrinolysis, 177 HC. See Hypercholesterolemia
Lp(a) and, 394 Helsinki Heart Study, 351
in tissue remodeling, 380 Hematopoietic colony-forming units (CFUs)
Fibrinolytic system, 177-178 and hypercholesterolemia, 32
fibrinolvtic gene expression, 178-180 and precursor cells with stromal potencies,
PAI and, 367-368, 394 25-30
Fibroblast growth factor (FGF), 420 Hemodynamics
Fish oils. See also Arachidonic acid; and atherogenesis localization, 86-88
Eicosapentaenoic acid and cell adhesion, 97-100
and cholesterol levels, 474-475, 479 and GMP-140 expression, 19
and fibrinogen levels, 467 shear stress
ANNALS NEW YORK ACADEMY OF SCIENCES
and atherosclerosis, 86-88 Hypercholesterolemia (HC). See also
distribution, 90-95 Familial hypercholesterolemia;
Hemorrhagic stroke, 486-488 Polygenic hypercholesterolemia
Hemostasis, PAI-1 in, 368, 375 and atherogenesis, 40-41, 44-47
Heparin, 634-636 and CAD, 283-291
Heparin-binding EGF-like growth factor EC proliferation in, 33
(HB-EGF) endothelium-dependent vasodilation
and atherosclerotic lesions, 123 impairment in, 622-625
in fibroproliferative response, 2 LDL-apheresis therapy for, 429-437. See
Hepatic lipase (HL), 626, 628 also LDL-apheresis regression study
Hepatic triglyceride lipase (HTGL), 599 LDL receptors and, 217
activities of, 600-602 Hyperemia, 197-199
Hyperfibrinogenemia, 562, 568-569
in VHDL formation, 607
Hyperglycemia, 562, 568-569
Hepatomegaly/hepatic carcinogenesis, 640
Hyperlipidemia. See Hypercholesterolemia
Herpes simplex virus (HSV), 58-59, 66-68
Hypertension
Herpes viruses, 58
and arterial wall thickening, 534-537
High blood pressure, and CAD, 313,
as atherosclerosis risk factor, 343
316-317, 328
vascular abnormalities in, 317
High-density lipoprotein (HDL)
Hypertriglyceridemia, 315
antiatherogenic effect of, 599
Hypoalpha, 325
apolipoprotein composition of, 240-241,
251-252
liver uptake of, 253-259 I CAM.-1. See Intercellular adhesion
in RCT, 240-241, 246-254, 257-261 molecule-1
High-density lipoprotein cholesterol IDDM. See Insulin-dependent diabetes
(HDL-C) mellitus
alcohol intake and, 627-629 IFNy. See Interferon
CETP deficiency and, 628 IGF-1. See Insulin-like growth factor
High-density lipoprotein (HDL) levels IL. See Interleukins
in CAD-family children, 315 Inositol triphosphate (1P3), 2, 385
in CETP-deficient patients, 599, 602 Insulin-dependent diabetes mellitus
fish oils and, 422 (IDDM), 318
vs. LDL/VLDL levels, 314 Insulin-like growth factor (IGF-1), 2
NCEP definitions, 315 Integrin receptor (VLA-4), 124-125
and RCT, 249-261 Intercellular adhesion molecule-1 (ICAM-1),
High-probability of atherosclerosis zones 153, 155
(HP zones), 12, 15-16, 32-33 and CD11/CD18 binding, 124, 134,
High shear-stress regions 136-137, 141
cytokines and, 158-159, 526, 528
and atherogenesis, 106
and EC injury, 137-139, 144, 146, 475
EC characteristics in, 106
in ECs, 498-499
lipid deposition at, 104, 111-112
EPA effects on, 478-479
Z/M tight junction ratios in, 111, 113, 119
giant ECs and, 33
HL. See Hepatic lipase
in intracellular signal transduction,
15-HPODE. See Lipoperoxides 144-145
HSV. See Herpes simplex virus
lyso-PC up-regulation of, 541-542
HTGL. See Hepatic triglyceride lipase and xanthine oxidase activation, 134, 141
Human aortic endothelial cells (HAECs), Interferony (IFNy), 2, 50, 161, 279
15-25 and atherosclerotic lesions, 123
Human umbilical vein endothelial cells NOS induction by, 586-587
(HUVECs), 18, 22-25 Interleukin-1 (IL-1), 48, 50, 187
HUVECs. See Human umbilical vein in atheroma, 466
endothelial cells and atherosclerotic lesions, 123
Hyperalphalipoproteinemia (HALP), and cytokine expression, 160
599-602. fatty streak expression of, 46
See also Familial fish oils and, 475
hyperalphalipoproteinemia and ICAM expression, 158-159